Recently, Huadong Medicine announced that Sinclair, its global medical aesthetic operation platform, has made phased progress in the domestic clinical trials of several blockbuster medical aesthetic products. MaiLi Precise completed the follow-up of all subjects’ primary endpoints. Ellansé S-type S and Lanluma V completed subject enrollment. KIO021’s clinical trial was successfully launched.
MaiLi Precise is part of Huadong Medicine’s high-end hyaluronic acid product series. MaiLi Extreme has submitted a domestic registration application and is expected to be approved in 2025. Lanluma, suitable for face and body fillers, is the only regenerative product approved for buttock and thigh fillers. It has EU CE certification and is approved in 32 countries. In December 2022, it landed in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone.
Huadong Medicine has a rich reserve of medical aesthetic products in development, thanks to its global layout. In the first three quarters of 2024, Huadong Pharmaceutical Medical Aesthetics maintained steady growth. Xinkeli Aesthetics achieved operating income growth.
In overseas markets, Huadong Medicine Sinclair is also speeding up registration. MaiLi series products were approved in Singapore. KIO015 is in the EU CE certification review stage. Sinclair has registered and marketed its injectable pipeline in multiple markets. It has also initiated the registration of MaiLi in the US.
In October 2024, Sinclair hosted the 2024 WORLD EXPERT MEETING in Barcelona. Huadong Medicine expects its core product pipeline to enhance brand effect and competitiveness.
Related topic
Jacqueline Fernandez Shares Her Eco-Friendly Beauty and Wellness Secrets
Typology Debuts Sustainable Hotel Skincare Line with Groupe GM
Anne Hathaway Shares Her Skincare Secrets
